Key facts
- DRIEHAUS CAPITAL MANAGEMENT LLC filed SCHEDULE 13G/A for Xenon Pharmaceuticals Inc. Common Stock (XENE).
- Disclosed ownership: 4.9%.
- Date of event: 31 Dec 2025.
DRIEHAUS CAPITAL MANAGEMENT LLC - 31 Dec 2025 SCHEDULE 13G/A Report for Xenon Pharmaceuticals Inc. Common Stock (XENE)
- Filing Manager
- DRIEHAUS CAPITAL MANAGEMENT LLC
- Reporting Manager
- DRIEHAUS CAPITAL MANAGEMENT LLC
- Symbol
- XENE
- Shares outstanding
- 92,231,068 shares
- Disclosed Ownership
- 4,491,653 shares
- Ownership
- 4.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2026, 07:06:02 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Key filing fact
DRIEHAUS CAPITAL MANAGEMENT LLC disclosed 4.9% ownership in Xenon Pharmaceuticals Inc. Common Stock (XENE) on 31 Dec 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2026, 07:06.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (1)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4.9% | 4,491,653 | 0 | 4,491,653 | Janet McWilliams | General Counsel |
CIK / CUSIP context first